The company received orders worth Rs 18,298 crore so far in FY24 against its annual guidance of Rs 20,000 crore
The company should be able to close the gap in profit margins with India listed peers
Employee costs remain elevated despite a moderation in revenue growth
Demand for high-end healthcare facilities remains strong and Medanta is strategically cementing its footprint in north India.
Most global companies indicate continuing destocking pressures
The stock is up 51 percent in the last one year
Sales in October 2023 are estimated to have risen by 19 percent in top seven cities
A steady growth profile, strong regional presence, and a higher focus on radiology give the company an edge in a highly competitive industry
Complex and high value products are helping pharma companies overcome the price pressure in base generic drug business
The 11-member MC Pro Cricindex has risen by 3 percent since September while the Nifty was flat during this period
The company’s market share declined by 80 basis points in October from September 2023
The company has to rapidly grow its business volumes
While Safari is making the most of the opportunities, VIP remains in a weak spot
Coromandel International and Paradeep Phosphates have multiple value-accretive catalysts.
Piyush Goyal’s proposed meeting with the Tesla boss could not take place, delaying the electric carmaker’s India investment plan
A credible profitability roadmap for pharmacy is the ask
PI Industries, with superior execution and a solid business model, is on track to achieve its long-term strategic objectives
The stock is valued at 60 times estimated FY24 earnings, not significantly lower than United Spirits
Average monthly transacting customers on the food delivery platform rose sequentially for the second consecutive quarter
The thermal capacity awards target has been raised to 11,200 MW from 7,200 MW
India’s share in the global ER&D sourcing market is expected to increase more than three-fold by 2030, says LTTS CEO
High channel inventory, dismal pricing, weak cashflows, high leverage – all came together to hurt the overall business. In fact, a lot of things will have to improve before we could see a reason for any rerating
The company’s US revenues are projected to move closer to $900 million in FY24 and $1 billion in FY25, up from $148 million in FY15
Honasa is trading at a valuation in line with its peers in similar businesses notching up significantly higher margins
Long-term business potential is not affected by near-term headwinds